Is there an advantage of monitoring via exosome-based detection of EGFR mutations during treatment in non-small cell lung cancer patients?
We know that detection of EGFR mutations is very important for individual therapy. Nowadays FFPE samples are commonly using to detect the EGFR mutation status. But it has a few handicaps such as, tumor heterogeneity and non-repeatable, it is need to examine mutation statues of EGFR after each treatm...
Gespeichert in:
Veröffentlicht in: | Genetika (Beograd) 2023, Vol.55 (1), p.83-93 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We know that detection of EGFR mutations is very important for individual
therapy. Nowadays FFPE samples are commonly using to detect the EGFR
mutation status. But it has a few handicaps such as, tumor heterogeneity and
non-repeatable, it is need to examine mutation statues of EGFR after each
treatment regimen for individually treatment of NSCLC patients. Therefore,
there is still need to develop non-invasive and useable over and over again
approach for monitoring EGFR mutation statues and other genes for individual
therapy. So, we aim to examine whether exosomes are good target for
detection of EGFR mutation status or not. Pyrosequencing was used to detect,
EGFR mutation in FFPE and exosome samples in some NSCLC patients. For the
patients given different chemotherapy regime (n=28), PFS was evaluated
before and after treatment. In patients who were EGFR positive before
treatment, the median PFS for EGFR mutation-positive patients after
treatment was 101.7 weeks (95% CI: 0.09-3.21), while for patients who were
negative after treatment, the median PFS was 42.43 weeks (95% CI: 0.31-
10.52). Likewise, in patients who were EGFR negative before treatment and
EGFR mutation negative after treatment, the PFS was median 52 weeks (95% CI:
0.17-2.84), while in patients who were positive after treatment, the median
PFS was 27.57 weeks (95% CI: 0.35-5.58). We show that exosomes are good
tools for monitoring EGFR mutation status and exosomes can be use as
semi-invasive method for isolation of tumor DNAs for detection of mutation
statues for individually treatment of NSCLC patients. |
---|---|
ISSN: | 0534-0012 1820-6069 |
DOI: | 10.2298/GENSR2301083K |